Pharmacogenomic (PGx) Testing Pricing

Requesting pricing for pharmacogenomics (PGx) testing of the following genes. They have clinical utility and can support PGx testing if abnormalities are found and the patient is on or being considered for relevant meds:

Gene Implication Supports PGx Need if:

• CYP2D6 — Poor/ultrarapid metabolizers of antidepressants, opioids, beta blockers: Patient is on SSRIs, opioids, or cardiac meds
• CYP2C19 — Affects metabolism of SSRIs and clopidogrel: Patient has history of depression, heart disease
• SLCO1B1 — Statin sensitivity: Patient is on statins or has hyperlipidemia
• HLA-B15:02* — Carbamazepine/oxcarbazepine risk (SJS/TEN): Patient has seizure history or mood disorders
• VKORC1 / CYP2C9 — Warfarin sensitivity: Elderly, A-fib, or heart disease patients
• COMT, MTHFR — Behavioral/cognitive symptoms, chronic pain: Patient has anxiety, ADHD, or chronic pain
• UGT1A1 — Irinotecan sensitivity; liver function support: Less common, but valuable in oncology referral